No specific causative genes or inheritance patterns are certified in this packet. The disease definition identifies multiple etiological pathways: direct injury to the parathyroid glands (for example, during thyroid or neck surgery), hypomagnesemia, radioactive iodine therapy for hyperthyroidism, metabolic alkalosis, DiGeorge syndrome, and type I polyglandular autoimmune syndrome. Recognized subtypes include autoimmune, secondary, and hereditary forms, reflecting the heterogeneous etiology of the condition.

Diagnostic methods are not certified in this packet.

Three FDA-approved treatments carry ACTIVE market status. Palopegteriparatide (YORVIPATH) received NDA approval on August 9, 2024. Parathyroid hormone (NATPARA) received BLA approval on January 23, 2015. Ergocalciferol (DRISDOL) carries NDA approval with an approval date of January 11, 1941. All three agents have ACTIVE market status. The disease definition describes the therapeutic goal as restoring calcium and mineral balance in the body.

Natural history data is not certified in this packet.

Multiple clinical trials are enrolling. A Phase 3 study evaluating palopegteriparatide in adolescents with long-term hypoparathyroidism (NCT07706764), sponsored by Ascendis Pharma, began enrolling in April 2026 with a planned completion of August 2031. A Phase 3 trial of canvuparatide versus placebo in adults with hypoparathyroidism (NCT07699471), sponsored by MBX Biosciences, opened in August 2026. An observational study of cardiovascular effects of parathyroid hormone analogues in chronic hypoparathyroidism (NCT07707479), sponsored by the National and Kapodistrian University of Athens, began in April 2026.